Research Summaries

Nivolumab Slows Melanoma Growth Better than just Ipilimumab

ASCO Annual Meeting
May 31, 2015

Recently, researchers found that nivolumab (Opdivo) either given as a single treatment or in combination with ipilimumab (Yervoy) is more effective than treatment with ipilimumab alone for people with advanced melanoma. Both nivolumab and ipilimumab are types of immunotherapy that block two proteins called PD-1 and CTLA-4. By blocking these two proteins, the drugs are able to boost the body’s immune system to fight the cancer. 

Choosing Lymph Node Surgery Earlier May Be a Better Option for Some Patients with Oral Cancer

ASCO Annual Meeting
May 31, 2015

A new study provides clarification on the best time for patients to receive lymph node surgery for early-stage oral cancer. Oral cancer is often successfully treated with surgery to remove the tumor. However, the cancer can come back and spread to the lymph nodes in the neck.

The Side Effects of Whole Brain Radiation Therapy for Brain Metastases May Outweigh the Benefits for Some Patients

ASCO Annual Meeting
May 31, 2015

In a recent study, researchers found that radiation therapy to the whole brain after radiosurgery for cancer that has spread to the brain causes more thought and memory problems than just radiosurgery. Even though the additional radiation therapy controlled the cancer’s growth, it did not lengthen patients’ lives.

Improved Care and Treatment Helps Children with Cancer Live Longer and Better

ASCO Annual Meeting
May 31, 2015

A recent analysis of information from more than 34,000 children who participated in the Childhood Cancer Survivor Study shows that modern cancer care is reducing deaths from cancer and long-term side effects. Previous research has shown that up to 18% of childhood cancer survivors die within 30 years of diagnosis. While deaths from worsening or recurrent cancers tend to slow over time, deaths from other health-related reasons, such as long-term side effects tend to increase.

New Targeted Drug Slows Growth and Spread of Metastatic Breast Cancer

ASCO Annual Meeting
May 30, 2015

A large phase III study has found that a new targeted therapy, called palbociclib (Ibrance), delayed the growth and spread of advanced hormone receptor-positive breast cancer by roughly five months when combined with the standard hormonal therapy fulvestrant (Faslodex). This combination could become a new treatment option for women with hormone receptor-positive, HER2-negative breast cancer that has spread to other parts of the body.

Eribulin Helps People with Two Rare Types of Soft-Tissue Sarcoma Live Longer

ASCO Annual Meeting
May 30, 2015

Approximately 12,000 people will be diagnosed with a soft-tissue sarcoma in the United States this year. Currently, there are few treatment options available, especially for tumors that grow or spread to other parts of the body during treatment. However, recent research has shown that the chemotherapy eribulin (Halaven) may be a promising new treatment option for people with two types of rare soft-tissue sarcomas: leiomyosarcoma and adipocytic sarcoma, which is also called liposarcoma.

Daratumumab May Be an Effective Treatment for Multiple Myeloma

ASCO Annual Meeting
May 30, 2015

According to a recent small study, the drug daratumumab may work well as a treatment for multiple myeloma after other treatments have not worked. About 26,000 Americans are diagnosed with multiple myeloma every year. Despite recent advances, treatments usually stop working to control the cancer’s growth.

Daratumumab is a type of targeted therapy. Targeted therapy is a treatment that targets the cancer’s specific genes, proteins, or the tissue environment that contributes to cancer growth and survival.

Anastrazole Helps Reduce Breast Cancer Risk after DCIS for Postmenopausal Women

ASCO Annual Meeting
May 30, 2015

A large clinical trial suggests that anastrazole (Arimidex) may be a new option for preventing breast cancer after treatment for ductal carcinoma in situ (DCIS). DCIS is a non-invasive type of breast cancer. DCIS can usually be eliminated with a lumpectomy followed by radiation therapy. However, women with DCIS are at increased risk for developing invasive breast cancer in the same or opposite breast.

Some People with Melanoma May Not Need Extensive Lymph Node Surgery

ASCO Annual Meeting
May 30, 2015

According to the results of a recent study, people who have surgery to remove lymph nodes near a melanoma tumor live the same amount of time as those who are watched closely for signs of cancer. Lymph nodes are tiny, bean-shaped organs that fight infection. During melanoma surgery, doctors look for cancer that has spread to the lymph nodes. If melanoma is found in these lymph nodes, there is a higher risk of the cancer coming back after treatment.

Adding Chemotherapy Improves Survival for Men with High-Risk, Localized Prostate Cancer

ASCO Annual Meeting
May 30, 2015

A recent study shows that adding docetaxel (Docefrez, Taxotere) chemotherapy to the standard treatment of hormone therapy and radiation therapy helps men with high-risk, localized prostate cancer live longer. Having a high-risk, localized prostate cancer means that the tumor has grown throughout the prostate gland, the tumor has a high grade or Gleason score, and the man has a high prostate-specific antigen (PSA) level. The Gleason score is based on how much the tumor looks like healthy tissue when viewed under a microscope.

Pages

Subscribe to RSS - Research Summaries